Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 328

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 328
---
 cashless exercise feature allowing the holder to receive shares underlying the Maxim Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of
the Maxim Warrant for such shares. Each Maxim Warrant is exercisable until its expiration in August 2033. The Maxim Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of our
common stock at an issuance price per share that is less than the then-effective exercise price of the Maxim Warrants. The warrant holder has certain demand and piggyback registration rights.

219

New Series B Warrants

In August 2023, we issued warrants to certain investors to purchase 100,373 shares of our common stock at an exercise price per share of $1.50,
subject to adjustment as set forth in the warrant, or the New Series B Warrants. As of June 30, 2025, New Series B Warrants to purchase up to 3,509 shares of our common stock remained unexercised. The New Series B Warrants include a cashless
exercise feature allowing the holder to receive shares underlying the applicable New Series B Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable New Series B
Warrant for such shares. Each New Series B Warrant is exercisable until its expiration in August 2028. The New Series B Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of
our common stock at an issuance price per share that is less than the then-effective exercise price of the New Series B Warrants. The warrant holder is not a stockholder and has none of the rights of a stockholder until the warrant is exercised and
the shares of common stock are issued upon exercise.

Investors’ Rights Agreement

In August 2023, in connection with the issuance and sale of our Series C preferred stock, we entered into an Investors’ Rights Agreement,
or the IRA. The IRA grants certain rights to the holders of our outstanding redeemable convertible preferred stock, including certain registration rights with respect to the registrable securities held by them. The holders of these registrable
securities possess registration rights pursuant to the terms of the IRA and are described in additional detail below. As of the completion of this offering, after giving effect to the conversion of all outstanding shares of our redeemable
convertible preferred stock into 3,181